Cantor Fitzgerald lowered the firm’s price target on Humana to $360 from $391 and keeps a Neutral rating on the shares. Humana beat the quarter as expected and held 2024 guidance, also as expected, but some risk still remains, and Cantor still doesn’t have clarity on how de-risked the new 2025 guidance will be, nor the degree of conservatism assumed in reserves, the analyst tells investors in a research note. Cantor believes Humana won’t find its floor until 2025 EPS guidance is set conservatively.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HUM:
- Humana Inc Reveals Quarterly Financial Performance and Projections
- Humana no longer believes $6-$10 of adjusted EPS growth is appropriate for 2025
- Humana backs FY24 adjusted EPS view ‘approximately’ $16.00, consensus $16.36
- Humana reports Q1 adjusted EPS $7.23, consensus $6.12
- Notable companies reporting before tomorrow’s open
